Long-term agalsidase beta therapy is associated with improvements in pain and quality of life among patients with Fabry disease

被引：0
|
作者：
Guffon, N.
Germain, D. P.
Waldek, S.
Banikazemi, M.
Bushinsky, D. A.
Charrow, J.
Lee, P.
Loew, T.
Vedder, A. C.
Wilcox, W. R.
机构：
[1] Hop Edouard Herriot, Lyon, France
[2] Hop Europeen Georges Pompidou, Paris, France
[3] Hope Hosp, Manchester, Lancs, England
[4] Mt Sinai Sch Med, New York, NY USA
[5] Univ Rochester, Sch Med, Rochester, NY 14627 USA
[6] Childrens Mem Hosp, Chicago, IL 60614 USA
[7] UCL Natl Hosp Neurol & Neurosurg, London WC1N 3BG, England
[8] Univ Iowa Hosp & Clin, Iowa City, IA 52242 USA
[9] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands
[10] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
来源：
CLINICAL THERAPEUTICS | 2007年 / 29卷
关键词：
D O I：
10.1016/S0149-2918(07)80154-8
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：S31 / S31
页数：1
相关论文
共 50 条
  • [1] LONG-TERM OUTCOME OF AGALSIDASE BETA THERAPY IN 10 ADULT MALE PATIENTS WITH FABRY DISEASE AND RENAL ALLOGRAFT
    Tran, T. -C.
    Benistan, K.
    Froissart, M.
    Germain, D. P.
    CLINICAL THERAPEUTICS, 2009, 31 : S39 - S40
  • [2] Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: Findings from the Fabry Registry
    Watt, Torquil
    Burlina, Alessandro P.
    Cazzorla, Chiara
    Schoenfeld, Dorothee
    Banikazemi, Maryam
    Hopkin, Robert J.
    Martins, Ana Maria
    Sims, Katherine
    Beitner-Johnson, Dana
    O'Brien, Fanny
    Feldt-Rasmussen, Ulla
    GENETICS IN MEDICINE, 2010, 12 (11) : 703 - 712
  • [3] Sustained, long-term renal stabilization after 54 months of agalsidase β therapy in patients with Fabry disease
    Germain, Dominique P.
    Waldek, Stephen
    Banikazemi, Maryam
    Bushinsky, David A.
    Charrow, Joel
    Desnick, Robert J.
    Lee, Philip
    Loew, Thomas
    Vedder, Anouk C.
    Abichandani, Rekha
    Wilcox, William R.
    Guffon, Nathalie
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2007, 18 (05): : 1547 - 1557
  • [4] Effect of changing therapy from agalsidase beta to agalsidase alfa in patients with Fabry disease
    West, M
    Lemoine, K
    ACTA PAEDIATRICA, 2006, 95 : 136 - 136
  • [5] Beneficial effect of agalsidase beta on long term evolution of patients with Fabry disease and kidney transplant
    Pineda-Galindo, Luis F.
    Moranchel-Garcia, Leslie
    MOLECULAR GENETICS AND METABOLISM, 2016, 117 (02) : S95 - S95
  • [6] Impact of treatment with agalsidase beta on health-related quality of life in patients with Fabry disease
    Badia, X.
    Perez, P.
    Layola, M.
    Checa, D.
    Tutor, A.
    Alvarez, A.
    Torra, R.
    Torras, J.
    de Arriba, G.
    Garcia-Monco, C.
    Puig, J. M.
    Torregrosa, V.
    CLINICAL THERAPEUTICS, 2007, 29 : S31 - S31
  • [7] The Effectiveness of Long-Term Agalsidase Alfa Therapy in the Treatment of Fabry Nephropathy
    Feriozzi, Sandro
    Torras, Joan
    Cybulla, Markus
    Nicholls, Kathy
    Sunder-Plassmann, Gere
    West, Michael
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2012, 7 (01): : 60 - 69
  • [8] Long-term efficacy and safety of agalsidase alfa in women with Fabry disease
    Whybra, C.
    Kampmann, C.
    Miebach, E.
    Gal, A.
    Baron, K.
    Beck, M.
    JOURNAL OF INHERITED METABOLIC DISEASE, 2008, 31 : 107 - 107
  • [9] Clinical event status of patients with Fabry disease after long-term treatment with agalsidase beta and follow-up from The Fabry Registry
    Germain, Dominique P.
    Linthorst, Gabor E.
    Wilcox, William R.
    Weidemann, Frank
    Cizmarik, Marta
    Warnock, David G.
    MOLECULAR GENETICS AND METABOLISM, 2013, 108 (02) : S42 - S42
  • [10] Renoprotective Effect of Agalsidase Alfa: A Long-Term Follow-Up of Patients with Fabry Disease
    Cybulla, Markus
    Nicholls, Kathleen
    Feriozzi, Sandro
    Linhart, Ales
    Torras, Joan
    Vujkovac, Bojan
    Botha, Jaco
    Anagnostopoulou, Christina
    West, Michael L.
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (16)
12345